Inactive Instrument

Analyst Reco. Nivalis Therapeutics Inc Nasdaq

Equities

US65481J1097

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	Apr. 16	MT
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform	Apr. 12	MT
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform From Outperform	Apr. 11	MT
HC Wainwright Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $50	Apr. 11	MT
Guggenheim Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $55	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Morgan Stanley Downgrades Alpine Immune Sciences to Equalweight From Overweight, Raises Price Target to $65 From $47	Apr. 11	MT
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal	Apr. 11	MT
Morgan Stanley Adjusts Price Target on Alpine Immune Sciences to $47 From $30, Maintains Overweight Rating	Mar. 19	MT
Oppenheimer Raises Alpine Immune Sciences Price Target to $44 From $33, Maintains Outperform Rating	Mar. 19	MT
HC Wainwright Adjusts Alpine Immune Sciences Price Target to $50 From $32, Maintains Buy Rating	Mar. 19	MT
Wedbush Adjusts Alpine Immune Sciences' PT to $47 From $35, Maintains Outperform Rating	Mar. 14	MT
RBC Raises Price Target on Alpine Immune Sciences to $41 From $29, Keeps Outperform, Speculative Risk	Mar. 12	MT
Wolfe Research Initiates Alpine Immune Sciences With Outperform Rating, $44 Price Target	Feb. 15	MT
Oppenheimer Raises Alpine Immune Sciences Price Target to $33 From $30, Maintains Outperform Rating	Jan. 26	MT
Wedbush Raises Alpine Immune Sciences' PT to $35 From $26 After Updated Data From Study Evaluating Atacicep in IgA Nephropathy; Maintains Outperform Rating	Jan. 26	MT
RBC Raises Price Target on Alpine Immune Sciences to $29 From $22, Cites 'Attractive Setup,' Keeps Outperform, Speculative Risk	Jan. 09	MT
HC Wainwright Adjusts Price Target on Alpine Immune Sciences to $32 From $17, Keeps Buy Rating	Dec. 22	MT
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
Morgan Stanley Adjusts Price Target on Alpine Immune Sciences to $30 From $17, Maintains Overweight Rating	Nov. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Nivalis Therapeutics Inc Nasdaq

Equities

US65481J1097

Analyst Reco.

Filters